药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

未开盘 07-08 16:08:19

58.300

-2.200

-3.64%

最高61.600	最低57.700	成交量676.43万
今开60.500	昨收60.500	日振幅6.45%
总市值735.75亿	流通市值735.75亿	总股本12.62亿
成交额3.99亿	换手率0.54%	流通股本12.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":58.3,"timestamp":1783498099007,"preClose":60.5,"halted":0,"volume":6764252,"delay":0,"changeRate":-0.03636363636363641,"floatShares":1262000000,"shares":1262000000,"eps":1.119999,"marketStatus":"未开盘","change":-2.2,"latestTime":"07-08 16:08:19","open":60.5,"high":61.6,"low":57.7,"amount":399022773,"amplitude":0.064463,"askPrice":58.35,"askSize":30500,"bidPrice":58.3,"bidSize":23000,"shortable":3,"etf":0,"ttmEps":1.246346,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":60.5,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":0.775374,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2649966752","title":"大行评级丨里昂：上调药明合联目标价至82.6港元，维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649966752","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649966752?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:07","pubTimestamp":1783498027,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","02268","SG9999014674.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649662889","title":"里昂：升药明合联(02268)目标价至82.6港元 重申“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649662889","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649662889?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:43","pubTimestamp":1783496587,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，药明合联(02268)于2026至2028年将持续受惠早期至中期ADC研发投资的持续强劲、2026年上半年生物科技融资复苏，以及制药及生物科技企业对新技术平台的持续投入，预测公司上半年获取新项目数量将录得强劲增长，全球ADC外包市场份额提升，临床前收入增长预料超越临床后收入，支持以美元计值收入及经调整纯利增长超越指引。里昂维持药明合联“跑赢大市”评级，目标价由80.9港元上调至82.6港元。里昂目前预测2026至2028年收入增长33%、31%及28%，纯利增长11%、51%及33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995950","title":"大和：首予药明合联(02268)“买入”评级 列CXO首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995950","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995950?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:40","pubTimestamp":1783482019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，首次给予药明合联“买入”评级，目标价78港元，并列为中国CXO行业首选股之一，指出药明合联是全球领先的抗体药物偶联物合约研究、开发及生产组织，亦是全球最大的纯ADC CRDMO企业，2025年市场份额达24%，预期受惠于快速增长的ADC外包市场及公司全链条CRDMO服务能力，该公司将能持续取得更多市场份额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1521","BK1141","LU1880383366.USD","02186","01477","159992","KURE","LU0196878994.USD","LU0979878070.USD","06990","LU0819121731.USD","LU1046422090.SGD","LU3063872942.SGD","IE00B0JY6N72.USD","BK1515","09926","LU2242644610.SGD","LU0572944931.SGD","LU0052750758.USD","LU0588546209.SGD","LU0456846285.SGD","06955","LU0326950275.SGD","02359","IBBQ","LU0417516571.SGD","LU0348784397.USD","01530","01952","LU0320764599.SGD","06855","BK1191","CZA","00460","02268","01672","LU0348783233.USD","02269","06978","LU0051755006.USD","LU0516423091.SGD","BK1600","LU2476274308.USD","REVS","SG9999002463.SGD","MEDX","SG9999014674.SGD","LU0516422440.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649172951","title":"大行评级丨大和：首予药明合联目标价78港元，列为中国CXO行业首选股之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2649172951","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649172951?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:19","pubTimestamp":1783477161,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2488822045.USD","SG9999014674.SGD","02268","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661726","title":"药明合联(02268.HK)因期权获行使合计发行26.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661726","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648661726?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:49","pubTimestamp":1783082997,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02268","LU2488822045.USD","SG9999014674.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114095916","title":"药明合联于7月3日新增发行约26.32万股，涉资约107.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114095916","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114095916?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:47","pubTimestamp":1783082843,"startTime":"0","endTime":"0","summary":"药明合联(02268)于2026年7月3日公布翌日披露报表，披露公司通过股份期权行使等方式，新增发行普通股共计263,203股，占发行前已发行股本约0.0209%。发行价格介乎每股1.8024港元至7.501港元，合计募资约107.06万港元。发行完成后，公司已发行股数增至1,262,105,257股，库藏股份数为0股。\n根据公告，此次股份发行包括根据2021年及2023年首次公开发售前购股权计划向若干董事与其他参与人授予期权的行使，由公司董事会正式授权并符合香港联合交易所有限公司证券上市规则及相关法律法规的要求。公告由执行董事兼首席财务官席晓捷签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联于7月3日新增发行约26.32万股，涉资约107.06万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174395347","title":"异动解读｜药明合联盘中上涨3.91%，CXO板块延续强势叠加回购计划及券商推荐提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1174395347","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174395347?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:12","pubTimestamp":1783044773,"startTime":"0","endTime":"0","summary":"7月3日，药明合联盘中上涨3.91%，报59.9港元/股，成交额1.24亿港元。消息面上，CXO板块近期持续走强，同行业个股中金斯瑞生物科技涨3.04%、晶泰控股涨2.81%，板块联动效应延续。基本面方面，公司此前公布最高1亿美元股份回购计划，受托人已于5月以均价57.3港元回购570万股，耗资约3.27亿港元。交银国际将药明合联列为高景气度赛道中投资性价比较高的头部玩家重点推荐，国泰海通维持\"增持\"评级，目标价84.38港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184236426","title":"药明合联：7月2日增发279,500股普通股，涉资约136.72万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184236426","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184236426?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:41","pubTimestamp":1782996119,"startTime":"0","endTime":"0","summary":"药明合联(02268)于2026年7月2日发布公告，披露根据其2021年及2023年首次公开发售前购股权计划行使期权的结果，当日合计发行新股279,500股普通股，约占原已发行股本的0.02215%。发行价格介乎每股1.8024港元至7.501港元不等，涉及金额约136.72万港元。\n本次股份发行前，公司已发行普通股数为1,261,562,554股。本次发行完成后，公司已发行股本增至1,261,842,054股，库藏股保持为零。公司同时确认已遵守相关上市规则及 applicable 法规的要求。公告由执行董事兼首席财务官席晓捷签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联：7月2日增发279,500股普通股，涉资约136.72万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113244337","title":"药明合联发布6月股份变动月报，已发行股份增加255,049股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113244337","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113244337?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:41","pubTimestamp":1782996112,"startTime":"0","endTime":"0","summary":"药明合联于2026年7月2日发布截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本维持在100亿股普通股，面值为每股0.00005美元，注册股本总额仍为50万美元，与上月相比无变化。新增股份主要来自多笔股权激励计划的行权，当月通过行使公司若干购股权计划合计行使数量达255,049股，募资金额共计77.43万元人民币。此外，公告称当月并无股份回购或注销活动。截至2026年6月30日，公司已发行股份总数升至1,261,562,554股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500823","title":"药明合联(02268)根据股份计划发行27.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500823","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648500823?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:39","pubTimestamp":1782995986,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明合联(02268)发布公告，于2026年7月2日根据股份计划发行合计27.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02268","LU2488822045.USD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177433014","title":"异动解读｜药明合联盘中上涨3.16%，CXO板块持续走强叠加回购计划提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1177433014","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177433014?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:25","pubTimestamp":1782959105,"startTime":"0","endTime":"0","summary":"7月2日，药明合联盘中上涨3.16%，报59.05港元/股，成交额1.95亿港元。消息面上，CXO板块延续近期强势表现，同行业个股中金斯瑞生物科技涨5.31%、药明生物涨2.83%、晶泰控股涨1.96%，板块联动效应显著。此前交银国际研报将药明合联列为高景气度赛道中投资性价比较高的头部玩家予以重点推荐，叠加公司此前公布的最高1亿美元股份回购计划及国泰海通维持\"增持\"评级、目标价84.38港元，为股价形成支撑。公司未完成订单约14.89亿美元，同比增长50.3%，盈利可见性较强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376884","title":"物奇微科创板IPO已受理 公司Wi-Fi6AP芯片性能比肩国际主流","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647376884?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:55","pubTimestamp":1782730548,"startTime":"0","endTime":"0","summary":"在网络通信芯片领域，公司先后推出Wi-FiSTA芯片与Wi-FiAP芯片，全面布局从连接到中枢的核心环节。历经多年持续攻关，公司在Wi-FiAP芯片的射频前端架构设计、基带信号处理及SoC系统集成等关键技术领域实现重大突破，成功研发基于RISC-V架构、性能比肩国际主流的Wi-Fi6AP芯片，是截至目前极少数掌握自主知识产权并具备量供能力的中国内地企业，成为打破国际巨头在高端路由器芯片领域的长期垄断格局的重要力量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B1BXHZ80.USD","LU2237957811.SGD","LU0096362180.USD","LU1670711040.USD","BK4515","BK4598","BK4512","LU1935042991.SGD","HK0000914660.USD","LU2471134952.CNY","LU1162221912.USD","LU2931357623.SGD","LU0472753341.HKD","LU0170899867.USD","LU2023250843.SGD","BK4533","LU0158827781.USD","LU0466842654.USD","LU2237443895.HKD","AVGG","LU2462157665.USD","LU2065171402.SGD","SG9999015978.USD","LU2471134796.USD","LU2458330243.SGD","LU0795875169.SGD","LU0210533765.USD","IE00BGHQDM52.EUR","BK4551","LU1992135472.HKD","LU0072462426.USD","BK4543","LU2168564065.EUR","LU0106261372.USD","LU2265009873.SGD","LU0788109477.HKD","LU2125154778.USD","LU0823434740.USD","LU1852331112.SGD","LU2236285917.USD","BK4575","IE00B19Z9P08.USD","LU1934455863.HKD","LU2211815571.USD","LU2242649171.HKD","LU0726765562.USD","LU2023250504.SGD","SG9999002232.USD","LU0011850046.USD","LU2125909247.SGD","SGXZ81514606.USD","IE00BZ9MQY76.HKD","LU2750360997.AUD","LU2505996509.AUD","LU0738911758.USD","SG9999015986.USD","LU1232071149.USD","LU1301847155.USD","LU1934455277.USD","LU0158827948.USD","LU2023250330.USD","LU0348723411.USD","IE00B894F039.SGD","LU1674673428.USD","LU0256863811.USD","LU1803068623.USD","BK4612","LU0689626769.HKD","LU1868837136.USD","LU1003077747.HKD","LU0061474705.USD","LU0965509010.AUD","LU0820562030.AUD","IE00BJTD4V19.USD","IE00B7KXQ091.USD","IE0005OL40V9.USD","IE00B5949003.HKD","LU0545039389.USD","LU0320765646.SGD","LU2279689827.SGD","LU0353189680.USD","LU1066053197.SGD","LU2764262908.HKD","LU0820561909.HKD","HK0000532082.HKD","LU0553294199.USD","LU2746668974.SGD","LU2746668461.USD","LU0642271901.SGD","BK4585","LU0215105999.USD","AVGO","LU1242518857.USD","LU1629891620.HKD","LU2602419157.SGD","LU1989764664.SGD","LU2125909593.SGD","LU2456880835.USD","LU0133085943.USD","LU1066051811.HKD","LU2168564222.USD","IE00BWXC8680.SGD","LU1366192091.USD","LU0354030438.USD","IE00BMPRXQ63.HKD","LU0211328371.USD","LU0942090050.USD","LU2028103732.USD","SG9999011175.SGD","LU2089283258.USD","LU1366333091.USD","LU0057025933.USD","LU0787776722.HKD","BK4554","688981","LU0070217475.USD","LU0198837287.USD","LU2108987350.USD","LU2361044949.HKD","LU2403377893.USD","LU1064131342.USD","LU0784385840.USD","LU0211327993.USD","LU1066051498.USD","LU1323610961.USD","LU0006306889.USD","LU0957791311.USD","LU1642822529.SGD","LU2089284900.SGD","LU2463028550.USD","LU2461242641.AUD","LU0266013472.USD","LU0314104364.USD","LU0444973449.USD","LU1551013425.SGD","LU1868836591.USD","LU2272731782.SGD","LU0251132253.USD","LU1951200564.SGD","LU2355687059.USD","IE00B775SV38.USD","LU2347655073.USD","SG9999002224.SGD","IE00B4JS1V06.HKD","LU0353189763.USD","LU0795875086.SGD","LU2272731865.HKD","LU1815336760.USD","IE00BJTD4N35.SGD","LU1670756490.USD","IE00BFSS7M15.SGD","LU0689472784.USD","LU2347655156.SGD","LU0127658192.USD","IE00BMPRXR70.SGD","LU0210528500.USD","LU0174119429.USD","BK4605","LU2637965513.SGD","LU2237443622.USD","LU0056508442.USD","IE00BQXX3D17.EUR","LU0203202063.USD","LU1037948541.HKD","LU2764263203.CNY","LU1670710588.SGD","LU2361045086.USD","LU1244550494.USD","LU1988902786.USD","LU1670710661.SGD","BK1614","IE0009356076.USD","LU1974910355.USD","LU1917777945.USD","LU0225283273.USD","LU2111349929.HKD","LU0672654240.SGD","LU1670628061.USD","LU1280957306.USD","IE00B3PB1722.GBP","LU0784383803.USD","LU0957808578.USD","LU2322448957.HKD","LU0323591593.USD","LU1066051225.USD","LU2237443549.SGD","LU2417539215.USD","LU2473716301.USD","LU0080751232.USD","LU0053666078.USD","LU0234572021.USD","LU1316542783.SGD","SG9999003800.SGD","LU0511384066.AUD","LU0868494708.USD","LU1732799900.SGD","LU2264538146.SGD","LU1914381329.SGD","AVGX","LU1720051108.HKD","LU2471134523.USD","LU1868836757.USD","IE0004445015.USD","LU2054465674.USD","LU2756315664.SGD","LU0157215616.USD","LU1935043536.SGD","LU2092937221.SGD","AVGU","BK4581","LU2543165471.USD","LU0289961442.SGD","LU1935042215.USD","LU0949170772.SGD","SG9999001440.SGD","AVGW","LU1989764748.USD","LU2237443978.SGD","AVL","LU1923622614.USD","LU2271345857.HKD","LU2750360641.GBP","LU2247934214.USD","BK1607","BK1141","LU0345769128.USD","LU1145028129.USD","LU2756315318.SGD","LU2041044095.USD","LU0979878070.USD","LU0949170426.SGD","LU0238689110.USD","BK1610","LU2430703178.SGD","LU2462591277.SGD","LU0861579265.USD","IE0034235188.USD","IE00BK4W5M84.HKD","LU2357305700.SGD","LU2322448791.USD","LU0912757837.SGD","LU0203347892.USD","LU1992135399.USD","LU2213496289.HKD","LU0082616367.USD","LU2764263039.SGD","LU0417517546.SGD","LU1069344957.HKD","LU0784384876.USD","LU0048584097.USD","LU0661504455.SGD","LU2430703095.HKD","LU1670627923.USD","LU2023251221.USD","LU1778281490.HKD","LU2720916845.USD","LU1202635105.USD","IE00BKVL7J92.USD","IE00BN8TJ469.HKD","LU2999663052.SGD","LU2361044865.SGD","LU0784385170.HKD","IE00BJJMRX11.SGD","LU0345769631.USD","LU0256863902.USD","IE00BKPKM429.USD","LU2106854487.HKD","00981","SG9999014674.SGD","LU2065169927.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU0345770308.USD","IE00BDGV0183.EUR","LU0069063385.USD","IE00BK4W5L77.USD","LU2168564495.EUR","LU2272731600.USD","IE00BVYPNP33.GBP","LU0354030511.USD","LU2592432038.USD","LU2089985449.USD","IE00BVYPNQ40.USD","LU0889565833.HKD","IE00B42XCP33.USD","LU1718418525.SGD","LU2360032135.SGD","LU0234570918.USD","LU2168563687.JPY","IE00BMCWC346.EUR","IE00BKDWB100.SGD","LU0708995401.HKD","LU2125154935.USD","IE00BBT3K403.USD","LU0943347566.SGD","LU1732800096.USD","LU1674673691.USD","02268","LU2286300806.USD","LU2954938101.SGD","SG9999004303.SGD","LU0203345920.USD","LU2211814178.USD","LU0308772762.SGD","LU0345768740.USD","LU1720051017.SGD","LU0274383776.USD","IE00BN29S564.USD","LU1803068979.SGD","LU2242650005.HKD","LU0868494617.USD","LU1670711123.USD","LU2896262040.SGD","LU1923623000.USD","LU1400636574.HKD","IE00B3S45H60.SGD","HK0000914686.HKD","LU0965509283.SGD","LU1951198990.SGD","LU2430703251.USD","LU2237443382.USD","LU2487616109.SGD","LU0061474960.USD","LU0724617625.USD","IE00BLSP4239.USD","LU2250418816.HKD","LU2083900584.USD","LU0154236417.USD","LU0097036916.USD","LU2458330169.SGD","LU1037948897.HKD","LU0719512351.SGD","LU0310799852.SGD","IE00BLSP4452.SGD","LU2420271590.USD","LU0210536198.USD","IE00BYV24P56.USD","LU1712237335.SGD","IE00BQXX3C00.GBP","LU2237957902.USD","LU0965509101.SGD","LU1400636657.SGD","LU0187121727.USD","LU2065171311.SGD","LU2244417387.USD","LU0124676726.USD","LU2488822045.USD","LU0109391861.USD","SGXZ23171101.USD","LU1934455194.USD","LU0964807845.USD","LU1804176565.USD","LU2471134879.HKD","IE0004445239.USD","LU0203201768.USD","LU2065170008.USD","LU0061475181.USD","LU2210150020.SGD","IE0001KFT4U8.USD","SGXZ51526630.SGD","LU0476273544.USD","LU0079474960.USD","IE00BGHQF631.EUR","LU2237443465.HKD","LU1868837300.USD","LU1989772840.SGD","LU0345770993.USD","LU1267930490.SGD","IE00B19Z9Z06.USD","LU2505996681.GBP","IE00BJJMRY28.SGD","LU2360108059.USD","AVS","LU0345768153.USD","LU1400636491.USD","LU1691799644.USD","BK4141","IE00B1XK9C88.USD","LU0965508806.USD","LU1244550577.SGD","LU1244550221.USD","LU1814569148.SGD","LU0289739343.SGD","SG9999001424.SGD","IE00BJLML261.HKD","SGXZ99366536.SGD","IE00BMPRXN33.USD","LU0823434583.USD","LU1645745479.HKD","LU2360106780.USD","LU1548497426.USD","LU1035775433.USD","LU0143551892.USD","LU2462591350.SGD","IE00BQXX3F31.USD","BK1526","LU0081259029.USD","SG9999015945.SGD","LU1127390331.HKD","LU1868836914.USD","BK4566","IE00B775H168.HKD","SG9999000418.SGD","LU1267930730.SGD","LU0320765059.SGD","LU2298321311.HKD","LU1153585028.USD","LU1551013342.USD","LU0985320562.USD","LU0786609619.USD","BK4588","LU1989772923.USD","LU0276348264.USD","LU2210149790.SGD","LU0096364046.USD","LU2095319765.USD","LU2087625088.SGD","LU1935043023.USD","IE00BVYPNV92.GBP","LU0640476718.USD","BK1163","LU1935042488.USD","LU0109392836.USD","LU0444971666.USD","LU1623119135.USD","LU2063271972.USD","LU0316494557.USD","IE0034235303.USD","LU2433249047.HKD","LU0683600562.USD","LU2168564149.EUR","IE00BVYPNW00.USD","LU0820561818.USD","LU1242518931.SGD","SG9999015952.SGD","IE00BFSS8Q28.SGD","LU2860962120.EUR","LU1815333072.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187379034","title":"异动解读｜药明合联盘中上涨3.18%，CXO板块集体走强带动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1187379034","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187379034?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:09","pubTimestamp":1782698955,"startTime":"0","endTime":"0","summary":"6月29日，药明合联盘中上涨3.18%，报57.4港元/股，成交额1.1亿港元。消息面上，CXO板块今日集体走强，同行业个股中药明生物涨5.21%、康龙化成涨7.75%、药明康德涨3.92%、晶泰控股涨13.33%，板块共振效应明显。此前交银国际研报将药明合联列为高景气度赛道中投资性价比较高的头部玩家予以重点推荐，叠加公司此前公布的最高1亿美元股份回购计划及股东大会授权回购不超过已发行股本10%等资本运作举措，为股价提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155558638","title":"一周港股牛熊榜 | 晋景新能绩后表现强劲！周内领涨逾26%、九方智投回购后涨逾20%；滔搏跌近30%，耐克渠道风波拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1155558638","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155558638?lang=zh_cn&edition=full","pubTime":"2026-06-27 09:00","pubTimestamp":1782522007,"startTime":"0","endTime":"0","summary":"总结全周，恒生指数跌1252.95点或5.24%，恒生科技指数跌348.76点或7.57%。本周涨幅居前个股中，晋景新能因年度收入大增并实现扭亏为盈，股价累计上涨26.29%；九方智投控股受连续回购催化，本周累涨20.91%；首钢朗泽则因工业尾气生物合成无水乙醇项目取得进展，累计上涨20.49%。跌幅方面，博泰车联折价配售完成后股价承压，本周累计下跌35.31%；滔搏受耐克线上渠道传闻及一季度销售走弱拖累，累计下跌29.84%；曹操出行在AI出行、Robotaxi题材降温后回吐前期涨幅，本周累计下跌24.84%。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"一周港股牛熊榜 | 晋景新能绩后表现强劲！周内领涨逾26%、九方智投回购后涨逾20%；滔搏跌近30%，耐克渠...","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02382","06821","BK4588","06110","01783","BK4585","VXUS","02553","02692","02889","02268","02643","09636"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2646539273","title":"药明合联(02268.HK)：方园、钟曼娜获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646539273","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646539273?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:28","pubTimestamp":1782466122,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","SG9999014674.SGD","02268","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172506323","title":"异动解读｜药明合联盘中下跌3.08%，报55.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172506323","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172506323?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:38","pubTimestamp":1782445093,"startTime":"0","endTime":"0","summary":"6月26日，药明合联盘中下跌3.08%，报55.1港元/股，成交额2.33亿港元。药明合联所在的生命科学工具和服务行业中，板块整体表现偏弱，个股中，药明康德跌0.69%，药明生物跌1.63%，英矽智能跌6.02%，康龙化成涨1.61%，晶泰控股跌0.3%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124529929","title":"异动解读｜药明合联盘中上涨3.01%，交银国际推荐叠加CXO板块持续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1124529929","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124529929?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:01","pubTimestamp":1782356498,"startTime":"0","endTime":"0","summary":"6月25日，药明合联盘中上涨3.01%，报54.8港元/股，成交额1.49亿港元。消息面上，交银国际近期研报将药明合联列为高景气度赛道中投资性价比较高的头部玩家予以重点推荐。板块方面，CXO板块近日持续走强，前一交易日药明合联大涨超10%，药明康德、金斯瑞生物科技等同步上攻，板块回购增持浪潮叠加景气周期传导形成共振效应。行业内今日药明康德涨1.98%，药明生物涨1.29%，英矽智能涨9.43%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198800089","title":"异动解读｜药明合联盘中上涨3.05%，交银国际推荐叠加子公司获药明生物订单持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1198800089","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198800089?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:37","pubTimestamp":1782265046,"startTime":"0","endTime":"0","summary":"6月24日，药明合联盘中上涨3.05%，报50.6港元/股，成交额2197.89万港元。消息面上，交银国际近期研报指出医药行业上半年表现整体稳健，将药明合联列为高景气度赛道中投资性价比较高的头部玩家予以重点推荐。板块方面，生命科学工具和服务行业今日整体走强，金斯瑞生物科技涨4.78%，药明康德涨3.67%，药明生物涨1.54%，形成板块共振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001206","title":"医药板块逆市走高 山东新华制药(00719)涨23.59%、康诺亚-B(02162)涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001206","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001206?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:08","pubTimestamp":1782180500,"startTime":"0","endTime":"0","summary":"市场交易结构出现变化，医药与科技板块不再呈现明显跷跷板效应，医疗服务、CXO赛道带动板块韧性修复。临近二季度末，市场开始提前交易行业业绩预期，资金重点布局两大主线，分别为商业化放量提速的创新药标的，以及受益于投融资回暖的CXO、生命科学上游龙头。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU0516422366.SGD","LU0516423091.SGD","LU0052750758.USD","IE00BPRC5H50.USD","02268","LU0348783233.USD","LU0359202008.SGD","LU1242518857.USD","06990","LU2328871848.SGD","LU1880383366.USD","BK1576","09688","BK1191","02269","IE00B5MMRT66.SGD","LU0039217434.USD","BK1161","LU0856984785.SGD","LU0456827905.SGD","IE00B0JY6N72.USD","LU0307460666.USD","LU0326950275.SGD","LU0588546209.SGD","00719","LU1720050803.USD","LU0979878070.USD","LU2039709279.SGD","LU3063872942.SGD","LU0140636845.USD","LU0327786744.USD","09926","BK1589","159938","LU0320764599.SGD","09939","09995","LU1303224171.USD","01877","LU0359201612.USD","LU0417516902.SGD","02162","09969","LU0051755006.USD","SG9999002562.SGD","LU0516422952.EUR","BK1583","LU1251922891.USD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":0.2457},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.1777},{"period":"1year","weight":0.3235},{"period":"ytd","weight":-0.0403}],"compareEarnings":[{"period":"1week","weight":0.0576},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.0775},{"period":"1year","weight":0.0021},{"period":"ytd","weight":-0.0558}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}